Abstract
Neoadjuvant chemotherapy (NACT) is an emerging approach for locally advanced cervical cancer (LACC), while two-thirds of patients (pts) respond to it and pts without response benefit little. PD-1 inhibitors have exhibited promising role in recurrent or metastatic cervical cancer. Additionally, preclinical evidence for the activation and synergistic effects of NACT on PD-1 inhibitors supports the superiority of neoadjuvant immunotherapy. We designed this phase II study to evaluated the efficacy and safety of preoperative PD-1 inhibitor camrelizumab combined chemotherapy in pts with LACC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
